NASDAQ:RDHL

RedHill Biopharma (RDHL) Stock Forecast, Price & News

$0.51

-0.07 (-12.07%)

(As of 09/29/2023 ET)

Compare

Today's Range: $0.50
▼
$0.57
50-Day Range: $0.51
▼
$1.36
52-Week Range: $0.50
▼
$38.40

Volume: 329,515 shs
Average Volume: 223,326 shs
Market Capitalization: $2.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About RedHill Biopharma (NASDAQ:RDHL) Stock

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Price History

30 days | 90 days | 365 days | Advanced Chart

RDHL Stock News Headlines

September 22, 2023 | americanbankingnews.com

RedHill Biopharma (NASDAQ:RDHL) Shares Cross Below 200 Day Moving Average of $2.36

September 5, 2023 | finance.yahoo.com

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

September 29, 2023 | Weiss Ratings (Ad)

Overlooked AI Stock Gets Urgent "Buy"

We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.

August 17, 2023 | finance.yahoo.com

RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights

July 31, 2023 | finance.yahoo.com

RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

July 25, 2023 | finance.yahoo.com

RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise

July 21, 2023 | benzinga.com

What's Going On With RedHill Biopharma Stock Today

July 21, 2023 | finance.yahoo.com

RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds

September 29, 2023 | Porter and Company (Ad)

The Elites Are Waging War on Elon Musk — Here's Why…

Elon has helped unleash an opportunity that could create trillions in wealth for everyday Americans. So why does the deep state hate him for it?

July 21, 2023 | finance.yahoo.com

RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development

July 6, 2023 | technews.tmcnet.com

Phil and RedHill Biopharma Partner to Increase Access to Talicia®

June 12, 2023 | finanznachrichten.de

RedHill Biopharma Ltd.: RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights

June 12, 2023 | finance.yahoo.com

RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights

May 24, 2023 | bizjournals.com

Raleigh drug developer trims R&D pipeline, shifts resources

May 22, 2023 | finance.yahoo.com

RedHill Provides R&D Update

May 15, 2023 | finance.yahoo.com

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

May 9, 2023 | finance.yahoo.com

RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week

May 1, 2023 | finance.yahoo.com

RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting

April 28, 2023 | finanznachrichten.de

RedHill Biopharma Ltd.: RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights

April 28, 2023 | finance.yahoo.com

RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights

April 17, 2023 | finance.yahoo.com

Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet

April 11, 2023 | finance.yahoo.com

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

April 3, 2023 | finance.yahoo.com

RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering

March 30, 2023 | finance.yahoo.com

RedHill Biopharma Announces $6 Million Registered Direct Offering

March 23, 2023 | finance.yahoo.com

RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt

March 23, 2023 | finanznachrichten.de

RedHill Biopharma Ltd: RedHill Biopharma Announces Plan to Implement ADS Ratio Change

March 21, 2023 | finance.yahoo.com

RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders

See More Headlines

Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Company Calendar

Last Earnings: 8/17/2023
Today: 9/29/2023
Next Earnings (Estimated): 12/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RDHL
CUSIP: N/A
CIK: 1553846
Web: www.redhillbio.com
Phone: 972-3541-3131
Fax: 972-3541-3144
Employees: 113
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,670,000.00
Net Margins: 354.95%
Pretax Margin: -9.10%
Return on Equity: -328.99%
Return on Assets: 71.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.96
Quick Ratio: 0.78

Sales & Book Value

Annual Sales: $61.80 million
Price / Sales: 0.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($16.41) per share
Price / Book: -0.03

Miscellaneous

Outstanding Shares: 5,850,000
Free Float: 5,455,000
Market Cap: $2.98 million
Optionable: Optionable
Beta: 2.00

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Dror Ben-Asher (Age 57)
Co-Founder, CEO & Director
Comp: $734.59k

Mr. Gilead Raday MPhil (Age 48)
MSc, Chief Operating Officer
Comp: $445.38k

Mr. Adi Frish (Age 53)
Chief Corp. & Bus. Devel. Officer
Comp: $419.5k

Mr. Rick D. Scruggs (Age 63)
Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director
Comp: $607.05k

Mr. Razi Ingber (Age 39)
Chief Financial Officer

Ms. Alexandra Okmian
Sr. Bus. Devel. & Investor Relations Mang.

Dr. Reza Fathi Ph.D. (Age 68)
Sr. VP of R&D

Mr. Guy Goldberg (Age 47)
Chief Bus. Officer

Dr. June S. Almenoff F.A.C.P. (Age 66)
M.D., Ph.D., Chief Medical Officer

Ms. Patricia Anderson B.Sc. RAC
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

Cowen AND Company LLC
Bought 288,000 shares on 8/7/2023
Ownership: 7.328%

View All Institutional Transactions

RDHL Stock - Frequently Asked Questions

How have RDHL shares performed in 2023?: RedHill Biopharma's stock was trading at $5.6120 at the beginning of 2023. Since then, RDHL shares have decreased by 90.9% and is now trading at $0.51.
View the best growth stocks for 2023 here.
Are investors shorting RedHill Biopharma?: RedHill Biopharma saw a drop in short interest in September. As of September 15th, there was short interest totaling 5,600 shares, a drop of 27.3% from the August 31st total of 7,700 shares. Based on an average daily volume of 393,700 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are short sold.
View RedHill Biopharma's Short Interest.
When is RedHill Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our RDHL earnings forecast.
How were RedHill Biopharma's earnings last quarter?: RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its earnings results on Thursday, August, 17th. The biotechnology company reported $36.00 earnings per share (EPS) for the quarter. The biotechnology company earned $1.80 million during the quarter. RedHill Biopharma had a net margin of 354.95% and a negative trailing twelve-month return on equity of 328.99%.
When did RedHill Biopharma's stock split?: RedHill Biopharma's stock reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of RedHill Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?: RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."
How do I buy shares of RedHill Biopharma?: Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is RedHill Biopharma's stock price today?: One share of RDHL stock can currently be purchased for approximately $0.51.
How much money does RedHill Biopharma make?: RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $2.98 million and generates $61.80 million in revenue each year.
How many employees does RedHill Biopharma have?: The company employs 113 workers across the globe.
How can I contact RedHill Biopharma?: RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144.

This page (NASDAQ:RDHL) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial